Introduction: There is growing interest in accelerating adoptions of vaccines. This study examined factors that differentiate the acceptance and timing of uptake of the first shingles vaccine, Zostavax, among older adults in the U.S.

Methods: Data from Health and Retirement Study respondents who were aged ≥62 years in 2008 were analyzed to determine whether they received a shingles vaccination from 2006 to 2016. Multinomial logistic regression was used to examine the characteristics associated with vaccine uptake and timing.

Results: Of those eligible, 15.2% were vaccinated early (between 2006 and 2010), 20.2% were vaccinated later, and 64.6% remained unvaccinated 10 years after the shingles vaccine was introduced. Respondents more likely to be vaccinated were those who had higher education and income, experience with influenza vaccination, more frequent social interaction with friends, or were residing in an area with higher shingles vaccination rates.

Conclusions: Shingles vaccination rates vary by social and geographic characteristics. Efforts to improve and expedite vaccination and other new preventive measures should target specific populations and geographic areas.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10618697PMC
http://dx.doi.org/10.1016/j.focus.2023.100143DOI Listing

Publication Analysis

Top Keywords

shingles vaccine
12
shingles vaccination
12
vaccine uptake
8
older adults
8
shingles
6
vaccination
5
uptake older
4
adults identifying
4
identifying early
4
early nonadopters
4

Similar Publications

Background/objectives: Approved mRNA vaccines commonly use sequences modified with pseudouridine to enhance translation efficiency and mRNA stability. However, this modification can result in ribosomal frameshifts, reduced immunogenicity, and higher production costs. This study aimed to explore the potential of unmodified mRNA sequences for varicella-zoster virus (VZV) and evaluate whether codon optimization could overcome the limitations of pseudouridine modification.

View Article and Find Full Text PDF

Background/objectives: Vaccines have been recognized as one of the most effective public health interventions. However, vaccine-associated anaphylaxis, although rare, is a serious adverse reaction. The incidence of anaphylaxis related to non-COVID-19 vaccines in adults remains underreported.

View Article and Find Full Text PDF

Background: The success of vaccination programs depends on a complex interplay of logistical, social, and structural factors. The objective of this study was to analyze the different approaches to vaccine administration implemented by several Italian regions since the onset of the SARS-CoV-2 pandemic.

Methods: After careful qualitative review of information gathered from scientific articles, official reports (grey literature), contact with regional health authorities, and local health departments, five vaccination strategies across several Italian regions focusing on alternative vaccine providers and/or settings were identified.

View Article and Find Full Text PDF

Introduction: Patients with chronic inflammatory diseases are often treated with pharmacologic therapies that target the immune system and have an increased risk of infection. These risks can be reduced by vaccination against common pathogens. This quality improvement project aimed to increase pneumococcal and herpes zoster vaccination rates in patients with chronic inflammatory disease on biologic immunosuppressive therapy.

View Article and Find Full Text PDF

[Shingles, a vaccine-preventable disease: time to realize it].

Geriatr Psychol Neuropsychiatr Vieil

December 2024

Service hospitalo-universitaire de gériatrie clinique, centre hospitalier universitaire Grenoble-Alpes, Grenoble, France.

The risk of herpes zoster (HZ) and postherpetic neuralgia (PHN) increases rapidly after the age of 50 years old. The incidence of herpes zoster and PHN appears to be correctly measured albeit irregularly and the immediate and long-term complications are so poorly measured that the perception of a benign disease remains entrenched among professionals and in the general population. Because acute-phase treatments are only marginally effective in reducing the severity and duration of complications, zoster vaccines have been developed over the last twenty years.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!